Prevention of community-acquired and nosocomial pneumonia

Current Opinion in Pulmonary Medicine

Volumn 2, Issue 3, 1996, Pages 228-235

  Simberkoff, Michael S ^a   Santos, Maria R ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; ANTIINFECTIVE AGENT; BACTERIAL VACCINE; COTRIMOXAZOLE; DAPSONE; HAEMOPHILUS VACCINE; INFLUENZA VACCINE; PENTAMIDINE;

BACTERIAL PNEUMONIA; COMMUNICABLE DISEASE; CROSS INFECTION; EDUCATION; ENDOTRACHEAL INTUBATION; EQUIPMENT; HAND WASHING; HOSPITAL PERSONNEL; HUMAN; IMMUNOLOGY; INFECTION CONTROL; INSTRUMENT STERILIZATION; LOBAR PNEUMONIA; PATIENT CARE; PATIENT EDUCATION; PNEUMOCYSTIS PNEUMONIA; PNEUMONIA; PUBLIC HEALTH; REVIEW; STREPTOCOCCUS PNEUMONIAE; UNITED STATES; VIRUS PNEUMONIA;

ANTI-BACTERIAL AGENTS; ANTIFUNGAL AGENTS; BACTERIAL VACCINES; COMMUNITY-ACQUIRED INFECTIONS; CROSS INFECTION; DAPSONE; EQUIPMENT CONTAMINATION; HAEMOPHILUS VACCINES; HANDWASHING; HUMANS; INFECTION CONTROL; INFLUENZA VACCINES; INTUBATION, INTRATRACHEAL; PATIENT EDUCATION; PATIENT ISOLATION; PENTAMIDINE; PERSONNEL, HOSPITAL; PNEUMONIA; PNEUMONIA, BACTERIAL; PNEUMONIA, PNEUMOCOCCAL; PNEUMONIA, PNEUMOCYSTIS; PNEUMONIA, VIRAL; PUBLIC HEALTH; STERILIZATION; STREPTOCOCCUS PNEUMONIAE; TRIMETHOPRIM-SULFAMETHOXAZOLE COMBINATION; UNITED STATES;

EID: 0030132961     PISSN: 10705287     EISSN: None     Source Type: Journal    
DOI: 10.1097/00063198-199605000-00011     Document Type: Article

References (48)

1. Centers for Disease Control and Prevention: Pneumonia and influenza death rates-United States 1979-1994. MMWR Morb Mortal Wkly Rep 1995, 44:535-537.
2. Woodhead MA, Macfarlane JT, McCracken JS, Rose DH, Finch RG: Prospective study of the aetiology and outcome of pneumonia in the community. Lancet 1987, 1:671-674.
3. Ostergaard L, Andersen PL: Etiology of community-acquired pneumonia: evaluation by transtracheal aspiration, blood culture, or serology. Chest 1993, 104:1400-1407.
4. Fang GD, Fine M, Orloff J, Arisumi D, Yu VL, Kapoor W, Grayston JT, Wang SP, Kohler R, Muder RR, et al.: New and emerging etiologies for community-acquired pneumonia with implications for therapy: a prospective multicenter study of 359 cases. Medicine 1990, 69:307-316.
5. Bartlett JG, Mundy LM: Community-acquired pneumonia. N Engl J Med 1995, 333:1618-1624. This state-of-the-art review covers diagnosis, assessment of severity, and treatment of CAP.
6. Mundy LM, Auwaerter PG, Oldach D, et al.: Community-acquired pneumonia: impact of Immune status. Am J Respir Crit Care Med 1995, 152:1309-1315. In this prospective study of CAP at Johns Hopkins Hospital, in Baltimore, Maryland, most of the patients (57%) were immunosuppressed, most often by HIV infection.
7. Centers for Disease Control: Update on adult immunization: recommendations of the Immunization Practices Advisory Committee (ACIP): pneumococcal disease. MMWR Morb Mortal Wkly Rep 1991, 40:42-44.
8. Butler JC, Breiman RF, Campbell JF, Lipman HB, Broome CV, Facklam RR: Pneumococcal polysaccharide vaccine efficacy: an evaluation of current recommendations. JAMA 1993, 270:1826-1831. This article contains data on the serotype distribution of all S. pneumoniae isolates from blood or cerebrospinal fluid submitted to the Centers for Disease Control and Prevention in whom the vaccine status of the patient was known. Pneumococcal vaccine efficacy was calculated from a formula that is based on the assumption that vaccination has no effect on the incidence of nonvaccine-type infection. The large number of isolates allows vaccine efficacy estimates to be made for individual serotypes of S. pneumoniae and for subsets of patients.
9. Fine MJ, Smith MA, Carson CA, Meffe F, Sankey SS, Weissfeld LA, Detsky AS, Kapoor WN: Efficacy of pneumococcal vaccination in adults: a meta-analysis of randomized controlled trials. Arch Intern Med 1994, 154:2666-2677. This is a meta-analysis of nine randomized trials of pneumococcal vaccine efficacy involving 12 vaccine and control groups published between 1976 and 1987. The patients were divided into low- and high-risk groups.
10. Hofmann J, Cetron MS, Farley MM, Baughman WS, Facklam RR, Elliott JA, Deaver KA, Breiman RF: Prevalence of drug-resistant Streptococcus pneumoniae in Atlanta. N Engl J Med 1995, 333:481-486. From January to October 1994, 25% of the S. pneumoniae isolates from 431 patients were resistant to penicillin (7% were highly resistant with minimum inhibitory concentrations of 2 μg/mL or higher), 26% were resistant to trimethoprim-sulfamethoxazole, 15% were resistant to erythromycin, and 9% were resistant to cefotaxime.
11. Stein KE: Thymus-independent and thymus-dependent responses to polysaccharide antigens. J Infect Dis 1992, 165(suppl 1):S49-S52.
12. LaForce FM, Nichol KI, Xox NI: Influenza: virology, epidemiology, disease, and prevention. Am J Prev Med 1994, 10(suppl 1):31-44. This is a good review of influenza virus, including the epidemiology and clinical manifestations of the disease it causes, as well as the current vaccines. It includes an excellent summary of the target populations for vaccination and strategies for improving immunization. There is also a brief discussion of chemotherapy.
13. Centers for Disease Control and Prevention: Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 1995, 44:1-22. This annual set of recommendations contains a wealth of information about influenza virus, influenza vaccine, and recommendations for use of the vaccine or alternative chemoprophylaxis.
14. Margolis KL, Nichol KL, Poland GA, Pluhar RE: Frequency of adverse reactions to influenza vaccine in the elderly: a randomized, placebo-controlled trial. JAMA 1990, 264:1139-1141.
15. Govaert TME, Dinant GJ, Aretz K, Masurel N, Sprenger MJW, Knottnerus JA: Adverse reactions of influenza vaccine In elderly people: randomized double blind placebo controlled trial. BMJ 1993, 307:988-990.
16. Mullooly JP, Bennett MD, Hornbrook MC, Barker WH, Williams WW, Patriarca PA, Rhodes PH: Influenza vaccination programs for elderly persons: cost-effectiveness in a health maintenance organization. Ann Intern Med 1994, 121:947-952. In this report of a case-control study of pneumonia and influenza that was performed at the Kaiser Permanente Northwest Region health maintenance organization, non-use of influenza vaccine in high-risk patients was associated with an increased risk of hospitalization for influenza and pneumonia and increased risk of hospitalized death. The savings for the health maintenance organization were $6.11 for high-risk, elderly patients. Conversely, the health maintenance organization incurred a net cost of $4.82 for each vaccination of a non-high-risk elderly person.
17. Nichol KL, Margolis KL, Wuorenma J, Sternberg TV: The efficacy and cost effectiveness of vaccination against Influenza among elderly persons living in the community. N Engl J Med 1994, 331:778-784. The efficacy of influenza vaccination was studied in patients over 64 years of age who were enrolled in Group Health, Inc., a health maintenance organization in Minneapolis-St. Paul, over three consecutive "flu seasons." Vaccine recipients were generally sicker at baseline. However, during each year there was a significantly reduced risk of hospitalization for pneumonia and influenza, of hospitalization for all acute and chronic respiratory illnesses, and of mortality from all causes among the influenza vaccine recipients. Direct savings averaged $117 per year per person vaccinated.
18. Nichol KL, Lind A, Margolis KL, Murdoch M, McFadden R, Hauge M, Magnan S, Drake M: The effectiveness of vaccination against influenza in healthy, working adults. N Engl J Med 1995, 333:889-893. Young working adults (18 to 64 years of age) were enrolled in a double-blind, placebo-controlled study of influenza vaccine efficacy. The primary outcomes were upper respiratory illness, absenteeism from work because of upper respiratory illness, and visits to physicians because of upper respiratory illness. The authors noted significantly fewer upper respiratory illnesses, fewer days of sick leave because of upper respiratory illness, and fewer physician visits because of upper respiratory illness in the vaccinated subjects. The cost savings were estimated to be $46.85 per person vaccinated.
19. Centers for Disease Control and Prevention: Influenza and pneumococcal vaccine coverage levels among persons aged ≥ 65 years - United States. MMWR Morb Mort Wkly Rep 1995, 44:506-515. This report, based on data from the National Health Interview Survey, compares pneumococcal and influenza vaccine coverage levels in patients 65 years of age or older.
20. Farley MM, Stephens DS, Brachman PS, Harvey C, Smith JD, Wenger JD, and CDC Meningitis Surveillance Group: Invasive Haemophilus influenzas disease in adults: a prospective, population-base surveillance. Ann Intern Med 1992, 116:806-812.
21. Casadevall A, Dobroszycki J, Small C, Pirofski LA: Haemophilus influenzas type b bacteremia in adults with AIDS and at risk for AIDS. Am J Med 1992, 92:587-590.
22. Eskola J, Kayhty H, Takala AK, Peltola H, Ronnenberg PR, Kela E, Pekkanen E, McVerry PH, Makela PH: A randomized, prospective filed trial of a conjugate vacine in the protection of infants and young children against invasive Haemophilus influenzae, type b disease. N Engl J Med 1990, 323:1381-1387.
23. Centers for Disease Control and Prevention: Progress toward elimination of Haemophilus influenzae, type b disease among infants and children-United States, 1993-1994. MMWR Morb Mortal Wkly Rep 1995, 44:545-550. Provisional data from the National Notifiable Diseases Surveillance System, the National Bacterial Meningitis and Bacteremia Reporting System, and a multistate laboratory-based surveillance system indicate that the incidence of invasive Hib disease in children younger than 5 years of age fell to 1.7 cases per 100,000 population.
24. Centers for Disease Control and Prevention. Update on adult immunization: recommendations of the Immunization Practices Advisory Committee (ACIP): Haemophilus influenzae, type b. MMWR Morb Mortal Wkly Rep 1991, 40:40-41.
25. Cushion MT: Transmission and epidemiology. In Pneumocystis carinii pneumonia, 2nd ed. Edited by Walzer PD. New York; Marcel Dekker; 1993:123-140.
26. Stiller RA, Paradis IL, Jauber JH: Subclinical pneumonitis due to Pneumocystis carinii in a young adult with elevated antibody titers to Epstein-Barr virus. J Infect Dis 1992, 166:926-930.
27. Schneider MME, Hoepelman AIM, Schattenkerk JKME, et al.: A controlled trial of aerosolized pentamidine or trimethoprim-sulfamethoxazole as primary prophylaxis against Pneumocystis carinii pneumonia in patients with human immunodeficiency virus infection. N Engl J Med 1992, 327:1836-1841.
28. Hardy WD, Feinberg J, Finkelstein DM, Power ME, He W, Kaczka C, Frame PT, Holmes M, Waskin H, Fass RJ, et al.: A controlled trial of aerosolized pentamldine or trimethoprim-sulfamethoxazole as secondary prophylaxis against Pneumocystis carinii pneumonia in patients with human immunodeficiency virus infection. N Engl J Med 1992, 327:1842-1848.
29. Simonds RJ, Hughes WT, Feinberg J, Navin TR: Preventing Pneumocystis carinii pneumonia in persons infected with human immunodeficiency virus. Clin Infect Dis 1995, 21(suppl 1):S44-S48. This article summarizes the available information on available drugs and results of trials for prophylaxis of PCP in HIV-infected patients.
30. Horan TC, White JW, Jarvis WR: Nosocomial infection surveillance, 1984. MMWR Morb Mortal Wkly Rep 1986, 35:17SS-29SS.
31. Bartlett JG, O'Keefe PO, Tally FP, Louie TJ, Gorbach SL: Bacteriology of hospital-acquired pneumonia. Arch Intern Med 1986, 146:868-871.
32. Schaberg DR, Culver DH, Gaynes RP: Major trends in the microbial etiology of nosocomial infection. Am J Med 1991, 91 (suppl 3B):72S-75S.
33. Fagon JY, Chastre J, Domart Y, Trouillet JL, Pierre J, Darne C, Gibert C: Nosocomial pneumonia in patients receiving continuous mechanical ventilation: prospective analysis of 52 episodes with use of a protected specimen brush and quantitative culture techniques. Am Rev Respir Dis 1989, 139:877-884.
34. Tablan OC, Anderson LJ, Arden NH, Breiman RF, Butler JC, McNeil MM: The Hospital Infection Control Practices Advisory Committee: guideline for prevention of nosocomial pneumonia. Infect Control Hosp Epidemiol 1994, 15:587-627. These guidelines from the Hospital Infection Control Practices Advisory Committee are divided into two parts. Part I is a discussion of current (1994) issues on prevention of nosocomial pneumonia. Part II contains specific recommendations for prevention of nosocomial pneumonia. The scientific basis for each recommendation is summarized and the strength of each recommendation is clearly indicated. These guidelines are must reading for health care providers interested in the prevention of noscomial pneumonia.
35. Fedson DS, Harward MP, Reid RA, Kaiser DL: Hospital-based pneumococcal immunization: epidemiologic rationale from the Shenandoah study. JAMA 1990, 264:1117-1122.
36. Rello J, Ricart M, Ausina V, Net A, Prats G: Pneumonia due to Haemophilus influenzae among mechanically ventilated patients: incidence, outcome, and risk factors. Chest 1992, 102:1562-1565.
37. Centers for Disease Control and Prevention: Guidelines for preventing the transmission of Mycobacterium tuberculosis in health-care facilities. 1994. MMWR Morb Mortal Wkly Rep 1994, 43:1-132. These are revised guidelines for health care workers and facilities. They emphasize risk assessment; tuberculin skin test screening of patients and employees; early identification, isolation, and treatment of patients with infectious tuberculosis; engineering controls for facilities; and personal protective equipment.
38. Whimbey E, Couch RB, Englund JA, Andereeff M, Goodrich JM, Raad II, Lewis V, Mirza N, Luna MA, Baxter B, et al.: Respiratory syncytial virus pneumonia in hospitalized adult patients with leukemia. Clin Infect Dis 1995, 21:376-379. This is a study of nine cases of respiratory syncytial virus infection seen adult patients with leukemia. Five of the cases appeared to have been acquired nosocomially. There were six patients with pneumonia, five of whom died.
39. Doebbeling BN, Stanley GL, Sheetz CT, MA, Pfaller MA, Houston AK, Annis L, Li N, Wenzel R: Comparative efficacy of alternative handwashing agents in reducing nosocomial infection in intensive care units. N Engl J Med 1992, 327:88-93.
40. Marston BJ, Lipman HB, Breiman RF: Surveillance for legionnaires' disease: risk factors for morbidity and mortality. Arch Intern Med 1994, 154:2417-2422. This report of 3254 patients with legionnaires' disease submitted to the CDC between 1960 and 1989 indicates that 23% of the cases were nosocomial and that the risk of death was increased in nosocomial infection.
41. Sahn SA: Continuous lateral rotational therapy and nosocomial pneumonia. Chest 1991, 99:1263-1267.
42. Mahul P, Auboyer C, Jospe R, Ros A, Guerin C, Khouri E, Gallisz M, Dumont A, Gaudin O: Prevention of nosocomial pneumonia in intubated patients: respective role of mechanical secretions drainage and stress ulcer prophylaxis. Intensive Care Med 1992, 18:20-25.
43. Vallés J, Artigas A, Rello J, et al.: Continuous aspiration of subglottic secretions in preventing ventilator-associated pneumonia. Ann Intern Med 1995, 122:179-186.
44. 2-antagonists for stress ulcer prophylaxis: a meta-analysis on efficacy and pneumonia rate. Crit Care Med 1991, 19:942-949.
45. Selective Decontamination of the Digestive Tract Trialists' Collaborative Group: Meta-analysis of randomized controlled trial of selective decontamination of the digestive tract BMJ 1993, 307:525-532. This meta-analysis of 22 randomized trials compared the incidences of nosocomial pneumonia in patients assigned to SDD and placebo or no therapy. SDD significantly reduced the risk of nosocomial pneumonia.
46. Pennington JE: Immunological perspective in prevention and treatment of nosocomial pneumonia. Intensive Care Med 1992, 18:S35-S38.
47. The Intravenous Immunoglobulin Collaborative Study Group: Intravenous administration of standard immune globulins as compared with corelipopolysaccharide immune globulin in patients at high risk of post-surgical infection. N Engl J Med 1992, 327:234-240.
48. Baker CJ, Melish ME, Hall RT, Castro DT, Vasan U, Givner LB, and the Multicenter Group for the Study of Immune Globulin in Neonates: Intravenous immune globulin for the prevention of nosocomial infection in low-birth-weight neonates. N Engl J Med 1992, 327:213-219.